Robuta

https://www.trinitydelta.org/savolitinib-china-nda-acceptance-for-nsclc-with-met-ex14-skipping-mutations/ Trinity Delta Savolitinib China NDA acceptance for NSCLC with MET ex14 skipping mutations - Trinity... trinity delta savolitinib china nda https://www.trinitydelta.org/full-china-approval-for-savolitinib-in-met-ex14-mnsclc/ Trinity Delta Full China approval for savolitinib in MET ex14 mNSCLC - Trinity Delta trinity delta full china approval https://www.hutch-med.com/ph2-savo-plus-tagrisso-nsclc/ HUTCHMED - WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and... phase ib wclc savolitinib plus met https://www.trinitydelta.org/china-approval-of-savolitinib-for-nsclc-with-met-exon-14-skipping-alterations/ Trinity Delta China approval of savolitinib for NSCLC with MET exon 14 skipping alterations -... trinity delta china approval savolitinib